Literature DB >> 20479757

Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype.

C Conejero-Goldberg1, T M Hyde, S Chen, U Dreses-Werringloer, M M Herman, J E Kleinman, P Davies, T E Goldberg.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative condition characterized histopathologically by neuritic plaques and neurofibrillary tangles. The objective of this transcriptional profiling study was to identify both neurosusceptibility and intrinsic neuroprotective factors at the molecular level, not confounded by the downstream consequences of pathology. We thus studied post-mortem cortical tissue in 28 cases that were non-APOE4 carriers (called the APOE3 group) and 13 cases that were APOE4 carriers. As APOE genotype is the major genetic risk factor for late-onset AD, the former group was at low risk for development of the disease and the latter group was at high risk for the disease. Mean age at death was 42 years and none of the brains had histopathology diagnostic of AD at the time of death. We first derived interregional difference scores in expression between cortical tissue from a region relatively invulnerable to AD (primary somatosensory cortex, BA 1/2/3) and an area known to be susceptible to AD pathology (middle temporal gyrus, BA 21). We then contrasted the magnitude of these interregional differences in between-group comparisons of the APOE3 (low risk) and APOE4 (high risk) genotype groups. We identified 70 transcripts that differed significantly between the groups. These included EGFR, CNTFR, CASP6, GRIA2, CTNNB1, FKBPL, LGALS1 and PSMC5. Using real-time quantitative PCR, we validated these findings. In addition, we found regional differences in the expression of APOE itself. We also identified multiple Kyoto pathways that were disrupted in the APOE4 group, including those involved in mitochondrial function, calcium regulation and cell-cycle reentry. To determine the functional significance of our transcriptional findings, we used bioinformatics pathway analyses to demonstrate that the molecules listed above comprised a network of connections with each other, APOE, and APP and MAPT. Overall, our results indicated that the abnormalities that we observed in single transcripts and in signaling pathways were not the consequences of diagnostic plaque and tangle pathology, but preceded it and thus may be a causative link in the long molecular prodrome that results in clinical AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20479757      PMCID: PMC2953572          DOI: 10.1038/mp.2010.57

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  69 in total

Review 1.  Zinc finger proteins: new insights into structural and functional diversity.

Authors:  J H Laity; B M Lee; P E Wright
Journal:  Curr Opin Struct Biol       Date:  2001-02       Impact factor: 6.809

Review 2.  Vulnerability of select neuronal types to Alzheimer's disease.

Authors:  H Braak; K Del Tredici; C Schultz; E Braak
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 3.  Alzheimer's disease-do tauists and baptists finally shake hands?

Authors:  Amritpal Mudher; Simon Lovestone
Journal:  Trends Neurosci       Date:  2002-01       Impact factor: 13.837

4.  Epidermal growth factor induces oxidative neuronal injury in cortical culture.

Authors:  Y K Cha; Y H Kim; Y H Ahn; J Y Koh
Journal:  J Neurochem       Date:  2000-07       Impact factor: 5.372

Review 5.  Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.

Authors:  Michael T Lin; M Flint Beal
Journal:  Nature       Date:  2006-10-19       Impact factor: 49.962

Review 6.  A network dysfunction perspective on neurodegenerative diseases.

Authors:  Jorge J Palop; Jeannie Chin; Lennart Mucke
Journal:  Nature       Date:  2006-10-19       Impact factor: 49.962

7.  Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons.

Authors:  S D Ginsberg; S E Hemby; V M Lee; J H Eberwine; J Q Trojanowski
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

Review 8.  Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?

Authors:  Mark A Smith; Kelly L Drew; Akihiko Nunomura; Atsushi Takeda; Keisuke Hirai; Xiongwei Zhu; Craig S Atwood; Arun K Raina; Catherine A Rottkamp; Lawrence M Sayre; Robert P Friedland; George Perry
Journal:  Neurochem Int       Date:  2002-05       Impact factor: 3.921

9.  Patterns of brain activation in people at risk for Alzheimer's disease.

Authors:  S Y Bookheimer; M H Strojwas; M S Cohen; A M Saunders; M A Pericak-Vance; J C Mazziotta; G W Small
Journal:  N Engl J Med       Date:  2000-08-17       Impact factor: 91.245

10.  Where Notch and Wnt signaling meet. The presenilin hub.

Authors:  B De Strooper; W Annaert
Journal:  J Cell Biol       Date:  2001-02-19       Impact factor: 10.539

View more
  22 in total

1.  Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid-beta precursor protein.

Authors:  Julien Chapuis; Valérie Vingtdeux; Fabien Campagne; Peter Davies; Philippe Marambaud
Journal:  Hum Mol Genet       Date:  2011-02-28       Impact factor: 6.150

Review 2.  The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update.

Authors:  Laura Mahoney-Sanchez; Abdel Ali Belaidi; Ashley I Bush; Scott Ayton
Journal:  J Mol Neurosci       Date:  2016-09-19       Impact factor: 3.444

Review 3.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

Review 4.  Age, APOE and sex: Triad of risk of Alzheimer's disease.

Authors:  Brandalyn C Riedel; Paul M Thompson; Roberta Diaz Brinton
Journal:  J Steroid Biochem Mol Biol       Date:  2016-03-08       Impact factor: 4.292

5.  Presenilin 1 is necessary for neuronal, but not glial, EGFR expression and neuroprotection via γ-secretase-independent transcriptional mechanisms.

Authors:  Julien Bruban; Georgios Voloudakis; Qian Huang; Yuji Kajiwara; Md Al Rahim; Yonejung Yoon; Junichi Shioi; Miguel A Gama Sosa; Zhiping Shao; Anastasios Georgakopoulos; Nikolaos K Robakis
Journal:  FASEB J       Date:  2015-05-18       Impact factor: 5.191

Review 6.  APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease.

Authors:  Andrew B Wolf; Richard J Caselli; Eric M Reiman; Jon Valla
Journal:  Neurobiol Aging       Date:  2012-11-16       Impact factor: 4.673

Review 7.  Apolipoprotein e sets the stage: response to injury triggers neuropathology.

Authors:  Robert W Mahley; Yadong Huang
Journal:  Neuron       Date:  2012-12-06       Impact factor: 17.173

8.  APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms.

Authors:  C Conejero-Goldberg; J J Gomar; T Bobes-Bascaran; T M Hyde; J E Kleinman; M M Herman; S Chen; P Davies; T E Goldberg
Journal:  Mol Psychiatry       Date:  2014-02-04       Impact factor: 15.992

9.  Epigenetic signature and enhancer activity of the human APOE gene.

Authors:  Chang-En Yu; Eiron Cudaback; Jessica Foraker; Zachary Thomson; Lesley Leong; Franziska Lutz; James Anthony Gill; Aleen Saxton; Brian Kraemer; Patrick Navas; C Dirk Keene; Thomas Montine; Lynn M Bekris
Journal:  Hum Mol Genet       Date:  2013-07-25       Impact factor: 6.150

Review 10.  Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review.

Authors:  Erwin Lemche
Journal:  Curr Genomics       Date:  2018-11       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.